Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System

{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2024, 1, 1]], 'date-time': '2024-01-01T17:50:12Z', 'timestamp': 1704131412069}, 'posted': {'date-parts': [[2020, 6, 12]]}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'reference-count': 18, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2020, 6, 12]]}, 'abstract': '<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>New ' 'York City is the US epicenter of the coronavirus disease 2019 (COVID-19) pandemic. Early ' 'international data indicated that comorbidity contributes significantly to poor prognosis and ' 'fatality in patients infected with SARS-CoV-2. It is not known to what degree medical ' 'comorbidity and sociodemographic determinants impact COVID-19 mortality in the ' 'US.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Evaluation of ' 'de-identified electronic health records of 7,592 COVID-19 patients confirmed by SARS-CoV-2 ' 'lab tests in New York City. Medical comorbidites and outcome of mortality, and other ' 'covariates, including clinical, sociodemographic, and medication measures were assessed by ' 'bivariate and multivariate logistic regression ' 'models.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of common ' 'comorbid conditions (hypertension, chronic kidney disease, chronic obstructive pulmonary ' 'disease, asthma, obesity, diabetes, HIV, cancer), when adjusted for covariates, chronic ' 'kidney disease remained significantly associated with increased odds of mortality. Patients ' 'who had more than one comorbidities, former smokers, treated with Azithromycin without ' 'Hydroxychloroquine, reside within the boroughs of Brooklyn and Queens Higher had higher odds ' 'of death.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Increasing ' 'numbers of comorbid factors increase COVID-19 mortality, but several clinical and ' 'sociodemographic factors can mitigate risk. Continued evaluation of COVID-19 in large diverse ' 'populations is important to characterize individuals at risk and improve clinical ' 'outcomes.</jats:p></jats:sec>', 'DOI': '10.1101/2020.06.11.20128926', 'type': 'posted-content', 'created': {'date-parts': [[2020, 6, 12]], 'date-time': '2020-06-12T22:45:11Z', 'timestamp': 1592001911000}, 'source': 'Crossref', 'is-referenced-by-count': 10, 'title': 'Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare ' 'System', 'prefix': '10.1101', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-0938-5157', 'authenticated-orcid': False, 'given': 'An-Li', 'family': 'Wang', 'sequence': 'first', 'affiliation': []}, {'given': 'Xiaobo', 'family': 'Zhong', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yasmin L', 'family': 'Hurd', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2021010205300523000_2020.06.11.20128926v1.1', 'unstructured': 'City of New York. COVID-19: Data. Available at: ' 'https://www1.nyc.gov/site/doh/covid/covid-19-data.page.'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.2', 'unstructured': 'World Health Organization. Coronavirus disease (COVID-19) Pandemic. ' 'Available at: ' 'https://www.who.int/emergencies/diseases/novel-coronavirus-2019.'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.3', 'doi-asserted-by': 'crossref', 'unstructured': 'Grasselli G , Zangrillo A , Zanella A , et al. Baseline Characteristics ' 'and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs ' 'of the Lombardy Region, Italy. JAMA 2020.', 'DOI': '10.1001/jama.2020.5394'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.4', 'doi-asserted-by': 'crossref', 'unstructured': 'Guan WJ , Liang WH , Zhao Y , et al. Comorbidity and its impact on 1590 ' 'patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J ' '2020.', 'DOI': '10.1183/13993003.01227-2020'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.5', 'doi-asserted-by': 'crossref', 'unstructured': 'Wang D , Hu B , Hu C , et al. Clinical Characteristics of 138 ' 'Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in ' 'Wuhan, China. JAMA 2020.', 'DOI': '10.1001/jama.2020.1585'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.6', 'doi-asserted-by': 'publisher', 'DOI': '10.3346/jkms.2020.35.e132'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.7', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30566-3'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.8', 'doi-asserted-by': 'crossref', 'unstructured': 'Goyal P , Choi JJ , Pinheiro LC , et al. Clinical Characteristics of ' 'Covid-19 in New York City. N Engl J Med 2020.', 'DOI': '10.1056/NEJMc2010419'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.9', 'unstructured': 'Richardson S , Hirsch JS , Narasimhan M , et al. Presenting ' 'Characteristics, Comorbidities, and Outcomes Among 5700 Patients ' 'Hospitalized With COVID-19 in the New York City Area. JAMA 2020.'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.10', 'unstructured': 'Guan WJ , Ni ZY , Hu Y , et al. Clinical Characteristics of Coronavirus ' 'Disease 2019 in China. N Engl J Med 2020.'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.11', 'unstructured': 'Centers for Disease Control and Prevention. People at Higher Risk for ' 'Severe Illness. Available at: ' 'https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/index.html.'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.12', 'doi-asserted-by': 'crossref', 'unstructured': 'Jackson DJ , Busse WW , Bacharier LB , et al. Association of Respiratory ' 'Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2. J ' 'Allergy Clin Immunol 2020.', 'DOI': '10.1016/j.jaci.2020.04.009'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.13', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhang JJ , Dong X , Cao YY , et al. Clinical characteristics of 140 ' 'patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020.', 'DOI': '10.1111/all.14238'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.14', 'doi-asserted-by': 'crossref', 'unstructured': 'Yao X , Ye F , Zhang M , et al. In Vitro Antiviral Activity and ' 'Projection of Optimized Dosing Design of Hydroxychloroquine for the ' 'Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 ' '(SARS-CoV-2). Clin Infect Dis 2020.', 'DOI': '10.1093/cid/ciaa237'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.15', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(03)00806-5'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.16', 'doi-asserted-by': 'crossref', 'unstructured': 'Gautret P , Lagier JC , Parola P , et al. Hydroxychloroquine and ' 'azithromycin as a treatment of COVID-19: results of an open-label ' 'non-randomized clinical trial. Int J Antimicrob Agents 2020:105949.', 'DOI': '10.1016/j.ijantimicag.2020.105949'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.17', 'unstructured': 'U.S. Food and Drug Administration. Hydroxychloroquine or Chloroquine for ' 'COVID-19: Drug Safety Communication - FDA Cautions Against Use Outside ' 'of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm ' 'Problems. Available at: ' 'https://www.fda.gov/safety/medical-product-safety-information/hydroxychloroquine-or-chloroquine-covid-19-drug-safety-communication-fda-cautions-against-use.'}, { 'key': '2021010205300523000_2020.06.11.20128926v1.18', 'doi-asserted-by': 'crossref', 'unstructured': 'Rosenberg ES , Dufort EM , Udo T , et al. Association of Treatment With ' 'Hydroxychloroquine or Azithromycin With In-Hospital Mortality in ' 'Patients With COVID-19 in New York State. JAMA 2020.', 'DOI': '10.1001/jama.2020.8630'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2020.06.11.20128926', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 10, 28]], 'date-time': '2022-10-28T05:45:41Z', 'timestamp': 1666935941000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2020.06.11.20128926'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 6, 12]]}, 'references-count': 18, 'URL': 'http://dx.doi.org/10.1101/2020.06.11.20128926', 'relation': {}, 'published': {'date-parts': [[2020, 6, 12]]}, 'subtype': 'preprint'}